Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept tapering in lower-risk MDS
NCT05925504Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jul 2023
- Primary completion
- Jun 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of luspatercept in myelodysplastic syndrome (MDS), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Jul 2023; status: recruiting.
02
Drugs
luspatercept
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05925504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05925504.